Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant
The objective of this study is to prevent reactivation of herpes zoster during the first year after transplant.
VZV Infection After Bone Marrow Transplantation
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
|Official Title:||Randomized Trial of Long-Term Oral Acyclovir Usage to Prevent Varicella Zoster Virus Infection After Allogeneic Bone Marrow Transplant|
- VZV infection at one year
- VZV infection after discontinuation of prophylaxis
|Study Start Date:||June 1985|
|Study Completion Date:||July 2004|
Herpes zoster infection occurs in 30% of allogeneic hematopoietic cell transplant (HCT) recipients who had a history of varicella zoster virus (VZV) infection. A safe and effective prevention strategy has not been established.
77 marrow allograft recipients at risk for VZV reactivation were randomized to oral acyclovir 800 mg twice daily or placebo given from day 30 until day 365 and were followed for toxicity and clinical evidence of herpes zoster infection.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00209352
|United States, Washington|
|Fred Hutchinson Cancer Research Center|
|Seattle, Washington, United States, 98109|
|Principal Investigator:||Michael Boeckh, MD||Fred Hutchinson Cancer Research Center|